| [1] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
|
| [2] |
Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation[J]. N Engl J Med, 2012, 367(17):1587-1595.
|
| [3] |
Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial[J]. JAMA, 2014, 311(7):692-700.
|
| [4] |
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial[J]. JAMA, 2005, 293(21):2634-2640.
|
| [5] |
Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation[J]. N Engl J Med, 2006, 354(9):934-941.
|
| [6] |
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med, 1998, 339(10):659-666.
|
| [7] |
Buiatti A, von Olshausen G, Barthel P, et al. Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies[J]. Europace, 2017, 19(3):378-384.
|
| [8] |
Wang Y, Wang W, Yao J, et al. Second-generation cryoballoon vs. contact-force sensing radiofrequency catheter ablation in atrial fibrillation: a meta-analysis of randomized controlled trials[J]. J Interv Card Electrophysiol, 2021, 60(1):9-19.
|
| [9] |
Andrade J, Champagne J, Dubuc M, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial.[J].Circulation, 2019, 140(22):1779-1788.
|
| [10] |
Murray MI, Arnold A, Younis M, et al. Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials[J]. Clin Res Cardiol, 2018, 107(8):658-669.
|
| [11] |
Hakalahti A, Biancari F, Nielsen JC, et al. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibril-lation: systematic review and meta-analysis[J]. Europace, 2015, 17(3):370-378.
|
| [12] |
Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses[J]. Circ Arrhythm Electrophysiol, 2009, 2(4):349-361.
|
| [13] |
Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials[J]. Circ Arrhythm Electrophysiol, 2009, 2(6):626-633.
|
| [14] |
Bonanno C, Paccanaro M, La Vecchia L, et al. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials[J]. J Cardiovasc Med (Hagerstown), 2010, 11(6):408-418.
|
| [15] |
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction[J]. Circulation, 2016, 133(5):484-492.
|
| [16] |
Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic[J]. Circulation, 2009, 119(18):2516-2525.
|
| [17] |
李春盛. 心房颤动致心力衰竭的发生机制及处理[J/OL]. 中华心脏与心律电子杂志, 2015, 3(4):7-9.
|
| [18] |
Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction[J]. J Am Coll Cardiol, 1998, 32(3):695-703.
|
| [19] |
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study[J]. Circulation, 2003, 107(23):2920-2925.
|
| [20] |
Carlisle MA, Fudim M, DeVore AD, et al. Heart failure and atrial fibrillation, like fire and fury[J]. JACC Heart Fail, 2019, 7(6):447-456.
|
| [21] |
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association[J]. Circulation, 2022, 145(8):e153- e639.
|
| [22] |
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction[J]. Circulation, 2016, 133(5):484-492.
|
| [23] |
Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure[J]. N Engl J Med, 2008, 359(17):1778-1785.
|
| [24] |
Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry[J]. Eur Heart J, 2018, 39(48):4277-4284.
|
| [25] |
Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review[J]. JAMA, 2023, 329(10):827-838.
|
| [26] |
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med, 1998, 339(10):659-666.
|
| [27] |
Charitakis E, Metelli S, Karlsson LO, et al. Comparing efficacy and safety in catheter ablation strategies for atrial fibrillation: a network meta-analysis[J]. BMC Med, 2022, 20(1):193.
|
| [28] |
Sau A, Howard JP, Al-Aidarous S, et al. Meta-analysis of randomized controlled trials of atrial fibrillation ablation with pulmonary vein isolation versus without[J]. JACC Clin Electrophysiol, 2019, 5(8):968-976.
|
| [29] |
Clarnette JA, Brooks AG, Mahajan R, et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis[J]. Europace, 2018, 20(FI_3):f366-f376.
|
| [30] |
Parameswaran R, Al-Kaisey AM, Kalman JM. Catheter ablation for atrial fibrillation: current indications and evolving technologies[J]. Nat Rev Cardiol, 2021, 18(3):210-225.
|
| [31] |
Kistler PM, Chieng D, Sugumar H, et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the CAPLA randomized clinical trial[J]. JAMA, 2023, 329(2):127-135.
|
| [32] |
马长生, 董建增, 刘兴鹏, 等. 犬Marshall韧带与心房颤动的关系及其关键消融部位[J]. 中华心律失常学杂志, 2003, 7(1):50-53.
|
| [33] |
Derval N, Duchateau J, Denis A, et al. Marshall bundle elimination, pulmonary vein isolation, and line completion for a natomical ablation of persistent atrial fibrillation (Marshall-PLAN): prospective, single-center study[J]. Heart Rhythm, 2021, 18(4):529-537.
|
| [34] |
Valderrábano M, Peterson LE, Swarup V, et al. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial[J]. JAMA, 2020, 324(16):1620-1628.
|
| [35] |
Lador A, Peterson LE, Swarup V, et al. Determinants of outcome impact of vein of Marshall ethanol infusion when added to catheter ablation of persistent atrial fibrillation: a secondary analysis of the VENUS randomized clinical trial[J]. Heart Rhythm, 2021, 18(7):1045-1054.
|
| [36] |
Lai Y, Liu X, Sang C, et al. Effectiveness of ethanol infusion into the vein of Marshall combined with a fixed anatomical ablation strategy (the "upgraded 2C3L" approach) for catheter ablation of persistent atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2021, 32(7):1849-1856.
|
| [37] |
Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial[J]. Circulation, 2019, 140(22):1779-1788.
|
| [38] |
Shi LB, Rossvoll O, Tande P, et al. Cryoballoon vs. radiofrequency catheter ablation: insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study)[J]. Europace, 2022, 24(2):226-233.
|
| [39] |
Su WW, Reddy VY, Bhasin K, et al. Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: results from the multicenter STOP rersistent AF trial[J]. Heart Rhythm, 2020, 17(11):1841-1847.
|
| [40] |
唐闽. 脉冲电场消融治疗心房颤动[J/OL]. 中华心脏与心律电子杂志, 2022, 10(1):27-31.
|
| [41] |
Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fi brillation [J]. N Engl J Med, 2023, 389(18):1660-1671.
|
| [42] |
Kueffer T, Stettler R, Maurhofer J, et al. Pulsed-field vs cryoballoon vs radiofrequency ablation: outcomes after pulmonary vein isolation in patients with persistent atrial fibrillation[J]. Heart Rhythm, 2024, 21(8):1227-1235.
|
| [43] |
Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure[J]. J Am Coll Cardiol, 2013, 61(18):1894-1903.
|
| [44] |
Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial[J]. Circulation, 2016, 133(17):1637-1644.
|
| [45] |
Newman JD, O'Meara E, Böhm M, et al. Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol, 2024, 83(9):932-950.
|
| [46] |
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2024, 149(1):e1-e156.
|
| [47] |
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6):572-618.
|
| [48] |
Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. Europace, 2024, 26(4):euae043.
|
| [49] |
Ariyaratnam JP, Elliott AD, Mishima RS, et al. Identification of subclinical heart failure with preserved ejection fraction in patients with symptomatic atrial fibrillation[J]. JACC Heart Fail, 2023, 11(11):1626-1638.
|
| [50] |
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med, 2020, 383(14):1305-1316.
|
| [51] |
Kornej J, Schumacher K, Dinov B, et al. Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation[J]. Sci Rep, 2018, 8(1):12686.
|
| [52] |
Cai L, Yin Y, Ling Z, et al. Predictors of late recurrence of atrial fibrillation after catheter ablation[J]. Int J Cardiol, 2013, 164(1):82-87.
|
| [53] |
Rattka M, Pott A, Kühberger A, et al. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients[J]. Europace, 2020, 22(9):1328-1336.
|
| [54] |
Chen C, Zhou X, Zhu M, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials[J]. J Interv Card Electrophysiol, 2018, 52(1):9-18.
|
| [55] |
Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study[J]. J Am Coll Cardiol, 2017, 70(16):1949-1961.
|
| [56] |
Halabi SA, Qintar M, Hussein A, et al. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials[J]. JACC Clin Electrophysiol, 2015, 1(3):200-209.
|
| [57] |
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med, 2018, 378(5):417-427.
|
| [58] |
Parkash R, Wells GA, Rouleau J, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial[J]. Circulation, 2022, 145(23):1693-1704.
|
| [59] |
Lai Y, Liu X, Sang C, Long D, et al. Effectiveness of ethanol infusion into the vein of Marshall combined with a fixed anatomical ablation strategy (the "upgraded 2C3L" approach) for catheter ablation of persistent atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2021, 32(7):1849-1856.
|
| [60] |
Chen H, Li H, Chen D, et al. Ethanol marshall bundle elimination, pulmonary vein isolation, and linear ablation for atrial fibrillation with or without heart failure. Front Cardiovasc Med, 2024, 11:1486621.
|
| [61] |
Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation[J]. N Engl J Med, 2023, 389(18):1660-1671.
|
| [62] |
Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation for atrial fibrillation in patients with heart failure[J]. JACC Clin Electrophysiol, 2024:S2405-2500X(24)00351-00357.
|
| [63] |
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37):3627-3639.
|
| [64] |
Parwani AS, Kääb S, Friede T, et al. Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: rationale and design of the CABA-HFPEF-DZHK27 trial[J]. Eur J Heart Fail, 2024, 26(10):2203-2212.
|
| [65] |
Brignole M, Pentimalli F, Palmisano P, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial[J]. Eur Heart J, 2021, 42(46):4731-4739.
|
| [66] |
Andrade JG, Deyell MW, Macle L, et al. Progression of atrial fibrillation after cryoablation or drug therapy[J]. N Engl J Med, 2023, 388(2):105-116.
|
| [67] |
Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST)[J]. Europace, 2021, 23(3):362-369.
|
| [68] |
刘少稳, 魏勇. 重新认识心房颤动的心力衰竭并发症[J]. 临床心血管病杂志, 2024, 40(11):867-870.
|
| [69] |
Bergonti M, Ascione C, Marcon L, et al. Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model[J]. Eur Heart J, 2023, 44(35):3327-3335.
|
| [70] |
Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial)[J]. Circ Arrhythm Electrophysiol, 2014, 7(1):31-38.
|
| [71] |
Prabhu S, Costello BT, Taylor AJ, et al. Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial[J]. JACC Clin Electrophysiol, 2018, 4(8):999-1007.
|
| [72] |
Suzuki S, Kitai T, Skoularigis J, et al. Catheter ablation for atrial fibrillation in patients with heart failure: current evidence and future opportunities[J]. J Pers Med, 2023, 3(9):1394.
|
| [73] |
Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial[J]. Circ Arrhythm Electrophysiol, 2019, 12(12):e007731.
|
| [74] |
Asad Z, Yousif A, Khan MS, et al. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials[J]. Circ Arrhythm Electrophysiol, 2019, 12(9):e007414.
|
| [75] |
Oraii A, McIntyre WF, Parkash R, et al. Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction: a systematic review and meta-analysis[J]. JAMA Cardiol, 2024, 9(6):545-555.
|
| [76] |
Younes H, Noujaim C, Mekhael M, et al. Atrial fibrillation ablation as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF): evaluating the impact on patient survival[J]. Expert Rev Cardiovasc Ther, 2023, 21(2):111-121.
|
| [77] |
Verma A, Boersma L, Haines DE, et al. First-in-human experience and acute procedural outcomes using a novel pulsed field ablation system: the PULSED AF pilot trial[J]. Circ Arrhythm Electrophysiol, 2022, 15(1):e010168.
|
| [78] |
Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation for atrial fibrillation in patients with heart failure[J]. JACC Clin Electrophysiol, 2024:S2405-500X(24)00351-7.
|
| [79] |
La Fazia VM, Pierucci N, Mohanty S, et al. Atrial fibrillation ablation in heart failure with preserved ejection f raction[J]. Card Electrophysiol Clin, 2025, 17(1):53-62.
|
| [80] |
Fukui A, Tanino T, Yamaguchi T, et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction[J]. J Cardiovasc Electrophysiol, 2020, 31(3):682-688.
|
| [81] |
Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction[J]. Am J Cardiol, 2021, 142:66-73.
|
| [82] |
Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure results from the CABANA Trial[J]. Circulation, 2021, 143(14):1377-1390.
|
| [83] |
Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure[J]. Circulation, 2021, 144(11):845-858.
|
| [84] |
Zylla MM, Leiner J, Rahm AK, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction[J]. Circ Heart Fail, 2022, 15(9):e009281.
|
| [85] |
Reddy Y, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction[J]. Circulation, 2018, 138(9):861-870.
|
| [86] |
Camm AJ, Naccarelli GV, Mittal S, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(19):1932-1948.
|
| [87] |
Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial[J]. Circulation, 2021, 143(14):1377-1390.
|
| [88] |
Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial[J]. Circ Arrhythm Electrophysiol, 2020, 13(10):e008461.
|
| [89] |
Nomura Y, Harada M, Motoike Y, et al. Selvester QRS score predicts improvement of LVEF in atrial fibrillation patients with systolic heart failure[J]. Pacing Clin Electrophysiol, 2022, 45(5):619-628.
|
| [90] |
Wen S, Pislaru SV, Lin G, et al. Association of postprocedural left atrial volume and reservoir function with outcomes in patients with atrial fibrillation undergoing catheter ablation[J]. J Am Soc Echocardiogr, 2022, 35(8):818-828. e3.
|
| [91] |
Yu L, Jiang R, Sun Y, et al. Catheter ablation for persistent atrial fibrillation with left ventricular systolic dysfunction: who is the best candidate?[J]. Pacing Clin Electrophysiol, 2022, 45(5):629-638.
|